94. 原発性硬化性胆管炎 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 177 / 薬物数 : 120 - (DrugBank : 48) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 148
薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
11C-csar
University of Aarhus
2013 Phase 1 NCT01879735 Denmark
45 GY external radiations
Azienda Ospedaliera di Padova
2012 - NCT01549795 Italy
Acetylcysteine
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
2012 - EUCTR2012-004170-26-IT Italy
Acido deossicolico
DR. FALK PHARMA GMBH
2018 Phase 3 EUCTR2016-003367-19-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom
Acido obeticolico
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States
Alanine
Nakamoto Nobuhiro
2024 Phase 2 JPRN-jRCTs031230676 -
Aldafermin
NGM Biopharmaceuticals, Inc
2024 Phase 2/Phase 3 NCT06654726 United States
ALL-trans retinoic acid
Yale University
2018 Phase 2 NCT03359174 United States
2011 Phase 1 NCT01456468 United States
Aramchol meglumine
Galmed Pharmaceuticals Ltd
2025 Phase 2 NCT06095986 United States
Atra
Yale University
2011 Phase 1 NCT01456468 United States
Azathioprine
Osaka General Medical Center
2012 - JPRN-UMIN000029482 Japan
Tajiri Hitoshi
2012 Phase 2 JPRN-jRCTs051180120 -
AZT
Tajiri Hitoshi
2012 Phase 2 JPRN-jRCTs051180120 -
Befizal L.P. 400 MG, comprimé enrobé à LIBération prolongéE
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2020 Phase 3 EUCTR2019-001015-23-FR France
Bexotegrast
Pliant Therapeutics, Inc
2021 Phase 2 EUCTR2020-001428-33-NL Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
2021 Phase 2 EUCTR2020-001428-33-DE Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
2020 Phase 2 EUCTR2020-001428-33-BE Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Norway;United Kingdom;United States
2020 Phase 2 EUCTR2020-001428-33-AT Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
Bezafibrate
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2020 Phase 3 EUCTR2019-001015-23-FR France
Academic Medical Center
2017 Phase 2 EUCTR2014-001438-27-ES Netherlands;Spain
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2016 Phase 3 NCT02701166 Netherlands;Spain
Bezafibrate (400MG) IN addition TO standard 15-20 MG/KG/jour udca therapy
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04309773 France
Bezalip
Academic Medical Center
2017 Phase 2 EUCTR2014-001438-27-ES Netherlands;Spain
2015 - EUCTR2014-001438-27-NL Netherlands
Blood draw FOR THE laboratory assessment
Mayo Clinic
2025 Phase 2 NCT06905054 United States
Bromlein
National Nutrition and Food Technology Institute
2024 - NCT06351696 Iran, Islamic Republic of
BRS201
Brigham and Women's Hospital
2023 Phase 2 NCT05835505 United States
BTT1023
University of Birmingham
2015 Phase 2 NCT02239211 United Kingdom
BTT1023 IV infusion 20 MG/ML, 5 ML drug product
University of Birmingham
2015 Phase 2 EUCTR2014-002393-37-GB United Kingdom
Budesonide
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1997 Phase 1 NCT00004842 United States
C10ab02
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2020 Phase 3 EUCTR2019-001015-23-FR France
Capecitabine
Azienda Ospedaliera di Padova
2012 - NCT01549795 Italy
Cenicriviroc 150 MG
Tobira Therapeutics, Inc.
2016 Phase 2 NCT02653625 Canada;United States
Cilo
Gilead Sciences
2019 Phase 1 NCT04060147 United States
Cilofexor
GILEAD SCIENCES INCORPORATED
2019 Phase 3 EUCTR2019-000204-14-IT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
Gilead Sciences
2019 Phase 3 NCT03890120 Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;New Zealand;Spain;Switzerland;United Kingdom;United States
2016 Phase 2 NCT02943460 Austria;Canada;United Kingdom;United States
2016 Phase 1 NCT02808312 New Zealand;United States
Gilead Sciences, Inc.
2019 Phase 3 EUCTR2019-000204-14-GB Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-FR Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-FI Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-ES Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-DK Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-BE Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-AT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
Gilead Sciences, K.K.
2019 Phase 3 JPRN-jRCT2080224728 Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;New Zealand;Spain;Switzerland;US;United Kingdom
CIS-4-hydroxy-L-proline
RIEMSER Arzneimittel AG
2005 - EUCTR2005-001454-24-LT Lithuania
Cladribine
National Center for Research Resources (NCRR)
1994 Phase 2 NCT00004762 -
CM-101
ChemomAb Ltd
2022 Phase 2 EUCTR2019-002945-39-ES Israel;Spain;United Kingdom
2020 Phase 2 EUCTR2019-002945-39-GB Israel;United Kingdom
ChemomAb Ltd.
2020 Phase 2 NCT04595825 Germany;Israel;Spain;United Kingdom;United States
2019 Phase 1 NCT06037577 Israel
2019 Phase 2 EUCTR2018-004258-77-GB Israel;United Kingdom
Contrast media, magnetic resonance
Massachusetts General Hospital
2024 - NCT06252610 United States
CS0159
Cascade Pharmaceuticals, Inc
2023 Phase 2 NCT05896137 China
2021 Phase 1 NCT05082779 United States
Curcumin
John E. Eaton
2017 Phase 1/Phase 2 NCT02978339 United States
DHA
Beth Israel Deaconess Medical Center
2005 Phase 1 NCT00325013 United States
Docosahexaenoic acid
Beth Israel Deaconess Medical Center
2005 Phase 1 NCT00325013 United States
DUR-928
Durect
2018 Phase 2 NCT03394781 United States
Elafibranor
Ipsen Bioscience, Inc.
2023 Phase 2 EUCTR2022-002695-37-PT Canada;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2022-002695-37-ES Canada;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2022-002695-37-DE Canada;Germany;Italy;Portugal;Spain;United Kingdom;United States
Elafibranor 120 MG
Ipsen
2022 Phase 2 NCT05627362 Canada;Germany;Italy;Portugal;Spain;United Kingdom;United States
Elafibranor 80 MG
Ipsen
2022 Phase 2 NCT05627362 Canada;Germany;Italy;Portugal;Spain;United Kingdom;United States
Endoluminal bile duct brachytherapy
Azienda Ospedaliera di Padova
2012 - NCT01549795 Italy
Engineered recombinant human FGF19
NGM Biopharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-003392-30-NL France;Netherlands;United Kingdom;United States
2016 Phase 2 EUCTR2015-003392-30-GB France;Netherlands;United Kingdom;United States
Entyvio
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
2016 Phase 3 EUCTR2014-003942-28-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2014-003942-28-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
EP547
Escient Pharmaceuticals, Inc
2022 Phase 2 NCT05525520 Belgium;Canada;France;Israel;Netherlands;Spain;United Kingdom;United States
EP547 tablet 25MG
Escient Pharmaceuticals, Inc.
2022 Phase 2 EUCTR2021-002526-25-FR Belgium;Canada;France;Israel;Netherlands;Spain;United Kingdom;United States
EP547 tablet 75MG
Escient Pharmaceuticals, Inc.
2022 Phase 2 EUCTR2021-002526-25-FR Belgium;Canada;France;Israel;Netherlands;Spain;United Kingdom;United States
Erlotinib
Mayo Clinic
2009 Phase 1 NCT00955149 United States
Faecal microbiota transplant
University of Birmingham
2024 Phase 2 NCT06286709 United Kingdom
Fecal microbiota transplantation
Brigham and Women's Hospital
2016 Phase 1/Phase 2 NCT02424175 United States
Keio University, School of Medicine
2019 - JPRN-UMIN000036121 Japan
Fenofibrate
Mayo Clinic
2025 Phase 2 NCT06905054 United States
University of Miami
2010 Phase 1/Phase 2 NCT01142323 United States
Fluimucil*20CPR EFF 600MG
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
2012 - EUCTR2012-004170-26-IT Italy
Genetic analysis
Mayo Clinic
2002 - NCT01161992 United States
GFT505
Ipsen Bioscience, Inc.
2023 Phase 2 EUCTR2022-002695-37-PT Canada;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2022-002695-37-ES Canada;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2022-002695-37-DE Canada;Germany;Italy;Portugal;Spain;United Kingdom;United States
Gluten-free diet
Institute for Clinical and Experimental Medicine
2023 - NCT06026449 Czechia
Universitätsklinikum Hamburg-Eppendorf
2017 - NCT04006886 Germany
GS-6624
Gilead Sciences Inc
2013 Phase 2 EUCTR2012-002473-61-SE Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-IT Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-ES Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-DK Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States
GS-9674
GILEAD SCIENCES INCORPORATED
2019 Phase 3 EUCTR2019-000204-14-IT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
Gilead Sciences, Inc.
2019 Phase 3 EUCTR2019-000204-14-GB Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-FR Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-FI Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-ES Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-DK Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-BE Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-AT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2017 Phase 2 EUCTR2016-002442-23-GB Austria;Canada;United Kingdom;United States
2017 Phase 2 EUCTR2016-002442-23-AT Austria;Canada;United Kingdom;United States
HK-660S
CuromeBiosciences
2021 Phase 2 NCT05866809 Korea, Republic of
HK-660S 100MG
CuromeBiosciences
2025 Phase 2 NCT06975150 -
HK-660S 200MG
CuromeBiosciences
2025 Phase 2 NCT06975150 -
HTD1801
HighTide Biopharma Pty Ltd
2021 Phase 2 NCT03678480 -
2018 Phase 2 NCT03333928 Canada;United States
2017 Phase 1 NCT03099603 Australia
Humanised IGG1 monoclonal antibody against human eotaxin-2
ChemomAb Ltd
2022 Phase 2 EUCTR2019-002945-39-ES Israel;Spain;United Kingdom
2020 Phase 2 EUCTR2019-002945-39-GB Israel;United Kingdom
Hymecromone
Aparna Goel
2023 Phase 2 NCT05295680 United States
ICG
University of Aarhus
2013 Phase 1 NCT01879735 Denmark
INT-747, OCA
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States
IPN60190
Ipsen Bioscience, Inc.
2023 Phase 2 EUCTR2022-002695-37-PT Canada;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2022-002695-37-ES Canada;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2022-002695-37-DE Canada;Germany;Italy;Portugal;Spain;United Kingdom;United States
LB-P8 HIGH-dose
LISCure Biosciences
2025 Phase 2 NCT06699121 United States
LB-P8 LOW-dose
LISCure Biosciences
2025 Phase 2 NCT06699121 United States
Levovanox
UNIVERSITÀ DEGLI STUDI MILANO BICOCCA
2022 Phase 2 EUCTR2022-000875-37-IT Italy
Liver transplantation
Keio University Hospital
2016 - JPRN-UMIN000022897 Japan
LUM001
Lumena Pharmaceuticals LLC
2015 Phase 2 EUCTR2014-005558-21-GB United Kingdom;United States
Mirum Pharmaceuticals, Inc.
2014 Phase 2 NCT02061540 Canada;United Kingdom;United States
MBX-8025
CymaBay Therapeutics
2019 Phase 2 EUCTR2019-001760-30-PL Australia;Canada;Germany;Israel;Poland;United Kingdom;United States
2019 Phase 2 EUCTR2019-001760-30-GB Australia;Canada;Germany;Israel;Poland;United Kingdom;United States
Methionine
Medical University of Warsaw
2023 - NCT06026865 Poland
Metronidazole
Keio University, School of Medicine
2016 - JPRN-UMIN000021411 Japan
Mayo Clinic
2010 Phase 1 NCT01085760 United States
Minocycline
Mayo Clinic
2003 Phase 1 NCT00630942 United States
Mitomycin C
Li, Zhiping, M.D.
2012 Phase 2 NCT01688024 United States
Mizoribine
Osaka General Medical Center
2012 - JPRN-UMIN000029482 Japan
Tajiri Hitoshi
2012 Phase 2 JPRN-jRCTs051180120 -
MLN0002
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
2016 Phase 3 EUCTR2014-003942-28-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2014-003942-28-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
NGM282
NGM Biopharmaceuticals, Inc
2016 Phase 2 NCT02704364 France;Netherlands;United Kingdom;United States
NGM Biopharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-003392-30-NL France;Netherlands;United Kingdom;United States
2016 Phase 2 EUCTR2015-003392-30-GB France;Netherlands;United Kingdom;United States
Normal saline
Li, Zhiping, M.D.
2012 Phase 2 NCT01688024 United States
Norucholic acid
Dr. Falk Pharma GmbH
2025 Phase 3 NCT06886360 -
2019 Phase 3 EUCTR2016-003367-19-NL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-SE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-PL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-FI Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-DK Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-CZ Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-BE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-LT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-DE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-AT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
- Phase 3 EUCTR2016-003367-19-NO Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
Norudca
DR. FALK PHARMA GMBH
2018 Phase 3 EUCTR2016-003367-19-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom
Dr. Falk Pharma GmbH
2019 Phase 3 EUCTR2016-003367-19-NL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-SE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-PL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-GB Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-FR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-FI Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-DK Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-CZ Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-BE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-LT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-HU Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-DE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-AT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2014 - EUCTR2011-002754-31-BE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2013 Phase 2 EUCTR2011-002754-31-GB Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 Phase 2 NCT01755507 Austria;Germany;Norway
2012 Phase 2 EUCTR2011-002754-31-SE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2011-002754-31-NO Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-NL Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-LT Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-HU Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-FI Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-ES Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-DK Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-DE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-AT Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
- Phase 3 EUCTR2016-003367-19-NO Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
- Phase 3 EUCTR2016-003367-19-IE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom
Norursodeoxycholic acid
DR. FALK PHARMA GMBH
2018 Phase 3 EUCTR2016-003367-19-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom
Dr. Falk Pharma GmbH
2018 Phase 3 NCT03872921 Austria;Germany
2018 Phase 3 EUCTR2016-003367-19-GB Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-FR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-HU Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2014 - EUCTR2011-002754-31-BE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2013 Phase 2 EUCTR2011-002754-31-GB Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2011-002754-31-SE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2011-002754-31-NO Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-NL Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-LT Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-HU Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-FI Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-ES Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-DK Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-DE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-AT Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
- Phase 3 EUCTR2016-003367-19-IE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom
Norursodeoxycholic acid, NCA
Dr. Falk Pharma GmbH
2019 Phase 3 EUCTR2016-003367-19-NL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-SE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-PL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-FI Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-DK Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-CZ Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-BE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-LT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-DE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-AT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
- Phase 3 EUCTR2016-003367-19-NO Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
OCA
Intercept Pharmaceuticals
2015 Phase 2 NCT02177136 Austria;Belgium;France;Germany;Italy;Netherlands;Norway;Sweden;United Kingdom;United States
OCA 1,5 MG
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States
OCA 5 MG
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States
Oral vancomycin
Sacramento Pediatric Gastroenterology
2010 Phase 1 NCT02137668 United States
Stanford University
2012 Phase 3 NCT01802073 United States
University Hospital Birmingham NHS Foundation Trust
2022 - NCT05376228 United Kingdom
University of Milano Bicocca
2023 Phase 2 NCT05876182 Italy
Oral vancomycin and oral amoxicillin
University of Minnesota
2024 Early Phase 1 NCT06197308 United States
Orbcel-C
University of Birmingham
2018 Phase 1/Phase 2 NCT02997878 United Kingdom
Phenylbutyrate
Juntendo University
2014 - JPRN-UMIN000012782 Japan
Saiseikai Yokohama City Tobu Hospital
2010 - JPRN-UMIN000003802 Japan
PLN-74809
Pliant Therapeutics, Inc
2021 Phase 2 EUCTR2020-001428-33-NL Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
2021 Phase 2 EUCTR2020-001428-33-FR Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
2021 Phase 2 EUCTR2020-001428-33-DE Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
2020 Phase 2 EUCTR2020-001428-33-GB Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Norway;United Kingdom;United States
2020 Phase 2 EUCTR2020-001428-33-BE Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Norway;United Kingdom;United States
2020 Phase 2 EUCTR2020-001428-33-AT Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
Pliant Therapeutics, Inc.
2020 Phase 2 NCT04480840 Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
PRE liver transplantation laparoscopic hand assisted staging
Azienda Ospedaliera di Padova
2012 - NCT01549795 Italy
Probiotics
UMC Utrecht
2005 Phase 3 NCT00161148 Netherlands
Radiotracer injection
Massachusetts General Hospital
2024 - NCT06252610 United States
REC-H-FGF19
NGM Biopharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-003392-30-NL France;Netherlands;United Kingdom;United States
2016 Phase 2 EUCTR2015-003392-30-GB France;Netherlands;United Kingdom;United States
Ritivixibat
Albireo, an Ipsen Company
2023 Phase 2 NCT05642468 France;Italy;Poland;Spain
Rituximab
Keio University Hospital
2016 - JPRN-UMIN000022897 Japan
Rosuvastatin
Stanford University
2023 Early Phase 1 NCT05912387 United States
Same
Medical University of Warsaw
2023 - NCT06026865 Poland
Seladelpar
CymaBay Therapeutics
2019 Phase 2 EUCTR2019-001760-30-PL Australia;Canada;Germany;Israel;Poland;United Kingdom;United States
2019 Phase 2 EUCTR2019-001760-30-GB Australia;Canada;Germany;Israel;Poland;United Kingdom;United States
Gilead Sciences
2019 Phase 2 NCT04024813 Canada;Poland;United States
Simtuzimab
Gilead Sciences Inc
2013 Phase 2 EUCTR2012-002473-61-IT Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Simtuzumab
Gilead Sciences
2013 Phase 2 NCT01672853 Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Gilead Sciences Inc
2013 Phase 2 EUCTR2012-002473-61-IT Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Simvastatin 40MG
Annika Bergquist
2020 Phase 3 NCT04133792 Sweden
Siplizumab
Elizabeth C. Verna
2024 Phase 1 NCT06455280 United States
Sulfasalazine
Brigham and Women's Hospital
2018 Phase 2 NCT03561584 United States
TBC
ChemomAb Ltd
2022 Phase 2 EUCTR2019-002945-39-ES Israel;Spain;United Kingdom
2020 Phase 2 EUCTR2019-002945-39-GB Israel;United Kingdom
Thalidomide
Mayo Clinic
2006 Phase 2 NCT00953615 United States
Ucmsc
Fuzhou General Hospital
2017 Phase 1/Phase 2 NCT03516006 -
Udca
Fuzhou General Hospital
2017 Phase 1/Phase 2 NCT03516006 -
University of Tennessee
2010 Phase 1 NCT01088607 Canada;United States
Ursodeoxycholic acid
HighTide Biopharma Pty Ltd
2021 Phase 2 NCT03678480 -
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2003 Phase 2/Phase 3 NCT00059202 United States
University of Tennessee
2010 Phase 1 NCT01088607 Canada;United States
Ursofalk
Sahlgrenska Academy
2015 Phase 3 EUCTR2015-003310-24-SE Sweden
Ursolic acid
University of California, Davis
2017 Phase 1 NCT03216876 United States
Vancomicina cloridrato
UNIVERSITÀ DEGLI STUDI MILANO BICOCCA
2022 Phase 2 EUCTR2022-000875-37-IT Italy
Vancomycin
Elizabeth Carey
2020 Phase 2/Phase 3 NCT03710122 Canada;United States
Karolinska Institutet
2013 - EUCTR2009-018034-11-SE Sweden
Mayo Clinic
2010 Phase 1 NCT01085760 United States
Ochsner Health System
2016 - NCT03046901 United States
Stanford University
2007 Phase 1 NCT01322386 -
Tehran University of Medical Sciences
2015 Phase 4 NCT02605213 Iran, Islamic Republic of
University of Minnesota
2015 Phase 1 NCT02464020 United States
Vedolizumab
Takeda
2017 Phase 3 NCT03035058 -
Vedolizumab IV
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2014-003942-28-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
Vidofludimus calcium
Elizabeth Carey
2019 Phase 2 NCT03722576 United States
Volixibat
Mirum Pharmaceuticals, Inc.
2020 Phase 2 NCT04663308 Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Volixibat potassium
Mirum Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-003027-41-DE Canada;Germany;Israel;United Kingdom;United States
Xifaxan
Mayo Clinic
2012 Phase 1 NCT01695174 United States
University of Aarhus
2013 Phase 1 NCT01879735 Denmark
45 GY external radiations
Azienda Ospedaliera di Padova
2012 - NCT01549795 Italy
Acetylcysteine
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
2012 - EUCTR2012-004170-26-IT Italy
Acido deossicolico
DR. FALK PHARMA GMBH
2018 Phase 3 EUCTR2016-003367-19-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom
Acido obeticolico
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States
Alanine
Nakamoto Nobuhiro
2024 Phase 2 JPRN-jRCTs031230676 -
Aldafermin
NGM Biopharmaceuticals, Inc
2024 Phase 2/Phase 3 NCT06654726 United States
ALL-trans retinoic acid
Yale University
2018 Phase 2 NCT03359174 United States
2011 Phase 1 NCT01456468 United States
Aramchol meglumine
Galmed Pharmaceuticals Ltd
2025 Phase 2 NCT06095986 United States
Atra
Yale University
2011 Phase 1 NCT01456468 United States
Azathioprine
Osaka General Medical Center
2012 - JPRN-UMIN000029482 Japan
Tajiri Hitoshi
2012 Phase 2 JPRN-jRCTs051180120 -
AZT
Tajiri Hitoshi
2012 Phase 2 JPRN-jRCTs051180120 -
Befizal L.P. 400 MG, comprimé enrobé à LIBération prolongéE
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2020 Phase 3 EUCTR2019-001015-23-FR France
Bexotegrast
Pliant Therapeutics, Inc
2021 Phase 2 EUCTR2020-001428-33-NL Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
2021 Phase 2 EUCTR2020-001428-33-DE Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
2020 Phase 2 EUCTR2020-001428-33-BE Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Norway;United Kingdom;United States
2020 Phase 2 EUCTR2020-001428-33-AT Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
Bezafibrate
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2020 Phase 3 EUCTR2019-001015-23-FR France
Academic Medical Center
2017 Phase 2 EUCTR2014-001438-27-ES Netherlands;Spain
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2016 Phase 3 NCT02701166 Netherlands;Spain
Bezafibrate (400MG) IN addition TO standard 15-20 MG/KG/jour udca therapy
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04309773 France
Bezalip
Academic Medical Center
2017 Phase 2 EUCTR2014-001438-27-ES Netherlands;Spain
2015 - EUCTR2014-001438-27-NL Netherlands
Blood draw FOR THE laboratory assessment
Mayo Clinic
2025 Phase 2 NCT06905054 United States
Bromlein
National Nutrition and Food Technology Institute
2024 - NCT06351696 Iran, Islamic Republic of
BRS201
Brigham and Women's Hospital
2023 Phase 2 NCT05835505 United States
BTT1023
University of Birmingham
2015 Phase 2 NCT02239211 United Kingdom
BTT1023 IV infusion 20 MG/ML, 5 ML drug product
University of Birmingham
2015 Phase 2 EUCTR2014-002393-37-GB United Kingdom
Budesonide
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1997 Phase 1 NCT00004842 United States
C10ab02
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2020 Phase 3 EUCTR2019-001015-23-FR France
Capecitabine
Azienda Ospedaliera di Padova
2012 - NCT01549795 Italy
Cenicriviroc 150 MG
Tobira Therapeutics, Inc.
2016 Phase 2 NCT02653625 Canada;United States
Cilo
Gilead Sciences
2019 Phase 1 NCT04060147 United States
Cilofexor
GILEAD SCIENCES INCORPORATED
2019 Phase 3 EUCTR2019-000204-14-IT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
Gilead Sciences
2019 Phase 3 NCT03890120 Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;New Zealand;Spain;Switzerland;United Kingdom;United States
2016 Phase 2 NCT02943460 Austria;Canada;United Kingdom;United States
2016 Phase 1 NCT02808312 New Zealand;United States
Gilead Sciences, Inc.
2019 Phase 3 EUCTR2019-000204-14-GB Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-FR Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-FI Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-ES Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-DK Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-BE Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-AT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
Gilead Sciences, K.K.
2019 Phase 3 JPRN-jRCT2080224728 Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;New Zealand;Spain;Switzerland;US;United Kingdom
CIS-4-hydroxy-L-proline
RIEMSER Arzneimittel AG
2005 - EUCTR2005-001454-24-LT Lithuania
Cladribine
National Center for Research Resources (NCRR)
1994 Phase 2 NCT00004762 -
CM-101
ChemomAb Ltd
2022 Phase 2 EUCTR2019-002945-39-ES Israel;Spain;United Kingdom
2020 Phase 2 EUCTR2019-002945-39-GB Israel;United Kingdom
ChemomAb Ltd.
2020 Phase 2 NCT04595825 Germany;Israel;Spain;United Kingdom;United States
2019 Phase 1 NCT06037577 Israel
2019 Phase 2 EUCTR2018-004258-77-GB Israel;United Kingdom
Contrast media, magnetic resonance
Massachusetts General Hospital
2024 - NCT06252610 United States
CS0159
Cascade Pharmaceuticals, Inc
2023 Phase 2 NCT05896137 China
2021 Phase 1 NCT05082779 United States
Curcumin
John E. Eaton
2017 Phase 1/Phase 2 NCT02978339 United States
DHA
Beth Israel Deaconess Medical Center
2005 Phase 1 NCT00325013 United States
Docosahexaenoic acid
Beth Israel Deaconess Medical Center
2005 Phase 1 NCT00325013 United States
DUR-928
Durect
2018 Phase 2 NCT03394781 United States
Elafibranor
Ipsen Bioscience, Inc.
2023 Phase 2 EUCTR2022-002695-37-PT Canada;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2022-002695-37-ES Canada;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2022-002695-37-DE Canada;Germany;Italy;Portugal;Spain;United Kingdom;United States
Elafibranor 120 MG
Ipsen
2022 Phase 2 NCT05627362 Canada;Germany;Italy;Portugal;Spain;United Kingdom;United States
Elafibranor 80 MG
Ipsen
2022 Phase 2 NCT05627362 Canada;Germany;Italy;Portugal;Spain;United Kingdom;United States
Endoluminal bile duct brachytherapy
Azienda Ospedaliera di Padova
2012 - NCT01549795 Italy
Engineered recombinant human FGF19
NGM Biopharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-003392-30-NL France;Netherlands;United Kingdom;United States
2016 Phase 2 EUCTR2015-003392-30-GB France;Netherlands;United Kingdom;United States
Entyvio
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
2016 Phase 3 EUCTR2014-003942-28-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2014-003942-28-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
EP547
Escient Pharmaceuticals, Inc
2022 Phase 2 NCT05525520 Belgium;Canada;France;Israel;Netherlands;Spain;United Kingdom;United States
EP547 tablet 25MG
Escient Pharmaceuticals, Inc.
2022 Phase 2 EUCTR2021-002526-25-FR Belgium;Canada;France;Israel;Netherlands;Spain;United Kingdom;United States
EP547 tablet 75MG
Escient Pharmaceuticals, Inc.
2022 Phase 2 EUCTR2021-002526-25-FR Belgium;Canada;France;Israel;Netherlands;Spain;United Kingdom;United States
Erlotinib
Mayo Clinic
2009 Phase 1 NCT00955149 United States
Faecal microbiota transplant
University of Birmingham
2024 Phase 2 NCT06286709 United Kingdom
Fecal microbiota transplantation
Brigham and Women's Hospital
2016 Phase 1/Phase 2 NCT02424175 United States
Keio University, School of Medicine
2019 - JPRN-UMIN000036121 Japan
Fenofibrate
Mayo Clinic
2025 Phase 2 NCT06905054 United States
University of Miami
2010 Phase 1/Phase 2 NCT01142323 United States
Fluimucil*20CPR EFF 600MG
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
2012 - EUCTR2012-004170-26-IT Italy
Genetic analysis
Mayo Clinic
2002 - NCT01161992 United States
GFT505
Ipsen Bioscience, Inc.
2023 Phase 2 EUCTR2022-002695-37-PT Canada;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2022-002695-37-ES Canada;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2022-002695-37-DE Canada;Germany;Italy;Portugal;Spain;United Kingdom;United States
Gluten-free diet
Institute for Clinical and Experimental Medicine
2023 - NCT06026449 Czechia
Universitätsklinikum Hamburg-Eppendorf
2017 - NCT04006886 Germany
GS-6624
Gilead Sciences Inc
2013 Phase 2 EUCTR2012-002473-61-SE Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-IT Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-ES Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-DK Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
2013 Phase 2 EUCTR2012-002473-61-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States
GS-9674
GILEAD SCIENCES INCORPORATED
2019 Phase 3 EUCTR2019-000204-14-IT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
Gilead Sciences, Inc.
2019 Phase 3 EUCTR2019-000204-14-GB Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-FR Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-FI Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-ES Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-DK Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-BE Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2019 Phase 3 EUCTR2019-000204-14-AT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States
2017 Phase 2 EUCTR2016-002442-23-GB Austria;Canada;United Kingdom;United States
2017 Phase 2 EUCTR2016-002442-23-AT Austria;Canada;United Kingdom;United States
HK-660S
CuromeBiosciences
2021 Phase 2 NCT05866809 Korea, Republic of
HK-660S 100MG
CuromeBiosciences
2025 Phase 2 NCT06975150 -
HK-660S 200MG
CuromeBiosciences
2025 Phase 2 NCT06975150 -
HTD1801
HighTide Biopharma Pty Ltd
2021 Phase 2 NCT03678480 -
2018 Phase 2 NCT03333928 Canada;United States
2017 Phase 1 NCT03099603 Australia
Humanised IGG1 monoclonal antibody against human eotaxin-2
ChemomAb Ltd
2022 Phase 2 EUCTR2019-002945-39-ES Israel;Spain;United Kingdom
2020 Phase 2 EUCTR2019-002945-39-GB Israel;United Kingdom
Hymecromone
Aparna Goel
2023 Phase 2 NCT05295680 United States
ICG
University of Aarhus
2013 Phase 1 NCT01879735 Denmark
INT-747, OCA
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States
IPN60190
Ipsen Bioscience, Inc.
2023 Phase 2 EUCTR2022-002695-37-PT Canada;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2022-002695-37-ES Canada;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2022-002695-37-DE Canada;Germany;Italy;Portugal;Spain;United Kingdom;United States
LB-P8 HIGH-dose
LISCure Biosciences
2025 Phase 2 NCT06699121 United States
LB-P8 LOW-dose
LISCure Biosciences
2025 Phase 2 NCT06699121 United States
Levovanox
UNIVERSITÀ DEGLI STUDI MILANO BICOCCA
2022 Phase 2 EUCTR2022-000875-37-IT Italy
Liver transplantation
Keio University Hospital
2016 - JPRN-UMIN000022897 Japan
LUM001
Lumena Pharmaceuticals LLC
2015 Phase 2 EUCTR2014-005558-21-GB United Kingdom;United States
Mirum Pharmaceuticals, Inc.
2014 Phase 2 NCT02061540 Canada;United Kingdom;United States
MBX-8025
CymaBay Therapeutics
2019 Phase 2 EUCTR2019-001760-30-PL Australia;Canada;Germany;Israel;Poland;United Kingdom;United States
2019 Phase 2 EUCTR2019-001760-30-GB Australia;Canada;Germany;Israel;Poland;United Kingdom;United States
Methionine
Medical University of Warsaw
2023 - NCT06026865 Poland
Metronidazole
Keio University, School of Medicine
2016 - JPRN-UMIN000021411 Japan
Mayo Clinic
2010 Phase 1 NCT01085760 United States
Minocycline
Mayo Clinic
2003 Phase 1 NCT00630942 United States
Mitomycin C
Li, Zhiping, M.D.
2012 Phase 2 NCT01688024 United States
Mizoribine
Osaka General Medical Center
2012 - JPRN-UMIN000029482 Japan
Tajiri Hitoshi
2012 Phase 2 JPRN-jRCTs051180120 -
MLN0002
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
2016 Phase 3 EUCTR2014-003942-28-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2014-003942-28-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
NGM282
NGM Biopharmaceuticals, Inc
2016 Phase 2 NCT02704364 France;Netherlands;United Kingdom;United States
NGM Biopharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-003392-30-NL France;Netherlands;United Kingdom;United States
2016 Phase 2 EUCTR2015-003392-30-GB France;Netherlands;United Kingdom;United States
Normal saline
Li, Zhiping, M.D.
2012 Phase 2 NCT01688024 United States
Norucholic acid
Dr. Falk Pharma GmbH
2025 Phase 3 NCT06886360 -
2019 Phase 3 EUCTR2016-003367-19-NL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-SE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-PL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-FI Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-DK Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-CZ Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-BE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-LT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-DE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-AT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
- Phase 3 EUCTR2016-003367-19-NO Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
Norudca
DR. FALK PHARMA GMBH
2018 Phase 3 EUCTR2016-003367-19-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom
Dr. Falk Pharma GmbH
2019 Phase 3 EUCTR2016-003367-19-NL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-SE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-PL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-GB Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-FR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-FI Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-DK Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-CZ Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-BE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-LT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-HU Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-DE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-AT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2014 - EUCTR2011-002754-31-BE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2013 Phase 2 EUCTR2011-002754-31-GB Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 Phase 2 NCT01755507 Austria;Germany;Norway
2012 Phase 2 EUCTR2011-002754-31-SE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2011-002754-31-NO Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-NL Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-LT Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-HU Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-FI Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-ES Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-DK Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-DE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-AT Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
- Phase 3 EUCTR2016-003367-19-NO Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
- Phase 3 EUCTR2016-003367-19-IE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom
Norursodeoxycholic acid
DR. FALK PHARMA GMBH
2018 Phase 3 EUCTR2016-003367-19-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom
Dr. Falk Pharma GmbH
2018 Phase 3 NCT03872921 Austria;Germany
2018 Phase 3 EUCTR2016-003367-19-GB Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-FR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-HU Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2014 - EUCTR2011-002754-31-BE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2013 Phase 2 EUCTR2011-002754-31-GB Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2011-002754-31-SE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2011-002754-31-NO Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-NL Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-LT Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-HU Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-FI Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-ES Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-DK Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-DE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
2012 - EUCTR2011-002754-31-AT Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom
- Phase 3 EUCTR2016-003367-19-IE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom
Norursodeoxycholic acid, NCA
Dr. Falk Pharma GmbH
2019 Phase 3 EUCTR2016-003367-19-NL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-SE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-PL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-FI Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-DK Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-CZ Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2018 Phase 3 EUCTR2016-003367-19-BE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-LT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-DE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
2017 Phase 3 EUCTR2016-003367-19-AT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
- Phase 3 EUCTR2016-003367-19-NO Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
OCA
Intercept Pharmaceuticals
2015 Phase 2 NCT02177136 Austria;Belgium;France;Germany;Italy;Netherlands;Norway;Sweden;United Kingdom;United States
OCA 1,5 MG
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States
OCA 5 MG
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States
Oral vancomycin
Sacramento Pediatric Gastroenterology
2010 Phase 1 NCT02137668 United States
Stanford University
2012 Phase 3 NCT01802073 United States
University Hospital Birmingham NHS Foundation Trust
2022 - NCT05376228 United Kingdom
University of Milano Bicocca
2023 Phase 2 NCT05876182 Italy
Oral vancomycin and oral amoxicillin
University of Minnesota
2024 Early Phase 1 NCT06197308 United States
Orbcel-C
University of Birmingham
2018 Phase 1/Phase 2 NCT02997878 United Kingdom
Phenylbutyrate
Juntendo University
2014 - JPRN-UMIN000012782 Japan
Saiseikai Yokohama City Tobu Hospital
2010 - JPRN-UMIN000003802 Japan
PLN-74809
Pliant Therapeutics, Inc
2021 Phase 2 EUCTR2020-001428-33-NL Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
2021 Phase 2 EUCTR2020-001428-33-FR Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
2021 Phase 2 EUCTR2020-001428-33-DE Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
2020 Phase 2 EUCTR2020-001428-33-GB Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Norway;United Kingdom;United States
2020 Phase 2 EUCTR2020-001428-33-BE Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Norway;United Kingdom;United States
2020 Phase 2 EUCTR2020-001428-33-AT Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
Pliant Therapeutics, Inc.
2020 Phase 2 NCT04480840 Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States
PRE liver transplantation laparoscopic hand assisted staging
Azienda Ospedaliera di Padova
2012 - NCT01549795 Italy
Probiotics
UMC Utrecht
2005 Phase 3 NCT00161148 Netherlands
Radiotracer injection
Massachusetts General Hospital
2024 - NCT06252610 United States
REC-H-FGF19
NGM Biopharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-003392-30-NL France;Netherlands;United Kingdom;United States
2016 Phase 2 EUCTR2015-003392-30-GB France;Netherlands;United Kingdom;United States
Ritivixibat
Albireo, an Ipsen Company
2023 Phase 2 NCT05642468 France;Italy;Poland;Spain
Rituximab
Keio University Hospital
2016 - JPRN-UMIN000022897 Japan
Rosuvastatin
Stanford University
2023 Early Phase 1 NCT05912387 United States
Same
Medical University of Warsaw
2023 - NCT06026865 Poland
Seladelpar
CymaBay Therapeutics
2019 Phase 2 EUCTR2019-001760-30-PL Australia;Canada;Germany;Israel;Poland;United Kingdom;United States
2019 Phase 2 EUCTR2019-001760-30-GB Australia;Canada;Germany;Israel;Poland;United Kingdom;United States
Gilead Sciences
2019 Phase 2 NCT04024813 Canada;Poland;United States
Simtuzimab
Gilead Sciences Inc
2013 Phase 2 EUCTR2012-002473-61-IT Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Simtuzumab
Gilead Sciences
2013 Phase 2 NCT01672853 Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Gilead Sciences Inc
2013 Phase 2 EUCTR2012-002473-61-IT Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
Simvastatin 40MG
Annika Bergquist
2020 Phase 3 NCT04133792 Sweden
Siplizumab
Elizabeth C. Verna
2024 Phase 1 NCT06455280 United States
Sulfasalazine
Brigham and Women's Hospital
2018 Phase 2 NCT03561584 United States
TBC
ChemomAb Ltd
2022 Phase 2 EUCTR2019-002945-39-ES Israel;Spain;United Kingdom
2020 Phase 2 EUCTR2019-002945-39-GB Israel;United Kingdom
Thalidomide
Mayo Clinic
2006 Phase 2 NCT00953615 United States
Ucmsc
Fuzhou General Hospital
2017 Phase 1/Phase 2 NCT03516006 -
Udca
Fuzhou General Hospital
2017 Phase 1/Phase 2 NCT03516006 -
University of Tennessee
2010 Phase 1 NCT01088607 Canada;United States
Ursodeoxycholic acid
HighTide Biopharma Pty Ltd
2021 Phase 2 NCT03678480 -
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2003 Phase 2/Phase 3 NCT00059202 United States
University of Tennessee
2010 Phase 1 NCT01088607 Canada;United States
Ursofalk
Sahlgrenska Academy
2015 Phase 3 EUCTR2015-003310-24-SE Sweden
Ursolic acid
University of California, Davis
2017 Phase 1 NCT03216876 United States
Vancomicina cloridrato
UNIVERSITÀ DEGLI STUDI MILANO BICOCCA
2022 Phase 2 EUCTR2022-000875-37-IT Italy
Vancomycin
Elizabeth Carey
2020 Phase 2/Phase 3 NCT03710122 Canada;United States
Karolinska Institutet
2013 - EUCTR2009-018034-11-SE Sweden
Mayo Clinic
2010 Phase 1 NCT01085760 United States
Ochsner Health System
2016 - NCT03046901 United States
Stanford University
2007 Phase 1 NCT01322386 -
Tehran University of Medical Sciences
2015 Phase 4 NCT02605213 Iran, Islamic Republic of
University of Minnesota
2015 Phase 1 NCT02464020 United States
Vedolizumab
Takeda
2017 Phase 3 NCT03035058 -
Vedolizumab IV
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2014-003942-28-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
2016 Phase 3 EUCTR2014-003942-28-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States
Vidofludimus calcium
Elizabeth Carey
2019 Phase 2 NCT03722576 United States
Volixibat
Mirum Pharmaceuticals, Inc.
2020 Phase 2 NCT04663308 Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Volixibat potassium
Mirum Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-003027-41-DE Canada;Germany;Israel;United Kingdom;United States
Xifaxan
Mayo Clinic
2012 Phase 1 NCT01695174 United States